Short Interest in Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Rises By 284.5%

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totaling 245,772 shares, a growth of 284.5% from the April 15th total of 63,926 shares. Approximately 8.0% of the shares of the company are sold short. Based on an average daily volume of 325,146 shares, the short-interest ratio is currently 0.8 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Valion Bio, Inc. Common Stock currently has an average rating of “Sell”.

Valion Bio, Inc. Common Stock Price Performance

Shares of NASDAQ VBIO traded down $0.13 during midday trading on Wednesday, hitting $0.97. The company had a trading volume of 147,224 shares, compared to its average volume of 239,030. The company has a quick ratio of 20.13, a current ratio of 20.13 and a debt-to-equity ratio of 0.38. Valion Bio, Inc. Common Stock has a twelve month low of $0.72 and a twelve month high of $5.60. The business has a 50-day simple moving average of $1.01 and a two-hundred day simple moving average of $1.40. The firm has a market capitalization of $3.04 million, a price-to-earnings ratio of -0.14 and a beta of 1.86.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last announced its quarterly earnings data on Monday, March 30th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($408.00) by $406.97.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.